1. Home
  2. BHE vs AGIO Comparison

BHE vs AGIO Comparison

Compare BHE & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Benchmark Electronics Inc.

BHE

Benchmark Electronics Inc.

N/A

Current Price

$83.20

Market Cap

2.1B

Sector

Technology

ML Signal

N/A

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

N/A

Current Price

$28.33

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BHE
AGIO
Founded
1979
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
BHE
AGIO
Price
$83.20
$28.33
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$55.00
$38.88
AVG Volume (30 Days)
435.7K
1.2M
Earning Date
04-29-2026
04-29-2026
Dividend Yield
0.94%
N/A
EPS Growth
N/A
N/A
EPS
0.36
N/A
Revenue
$2,659,108,000.00
$43,011,000.00
Revenue This Year
$7.03
$76.75
Revenue Next Year
$6.57
$170.73
P/E Ratio
$230.65
N/A
Revenue Growth
0.11
N/A
52 Week Low
$34.44
$22.24
52 Week High
$87.73
$46.00

Technical Indicators

Market Signals
Indicator
BHE
AGIO
Relative Strength Index (RSI) 59.09 49.56
Support Level $39.25 $26.42
Resistance Level $87.73 $29.39
Average True Range (ATR) 3.92 0.87
MACD -0.69 0.22
Stochastic Oscillator 62.15 73.03

Price Performance

Historical Comparison
BHE
AGIO

About BHE Benchmark Electronics Inc.

Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: